These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2327402)

  • 1. Leukemic transformation in polycythemia vera: analysis of risk factors.
    Nand S; Messmore H; Fisher SG; Bird ML; Schulz W; Fisher RI
    Am J Hematol; 1990 May; 34(1):32-6. PubMed ID: 2327402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of polycythemia vera with hydroxyurea.
    Donovan PB; Kaplan ME; Goldberg JD; Tatarsky I; Najean Y; Silberstein EB; Knospe WH; Laszlo J; Mack K; Berk PD
    Am J Hematol; 1984; 17(4):329-34. PubMed ID: 6496458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea in the treatment of polycythemia vera: a prospective study of 100 patients over a 20-year period.
    West WO
    South Med J; 1987 Mar; 80(3):323-7. PubMed ID: 3824016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
    Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
    Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemogenic risk of hydroxyurea therapy as a single agent in polycythemia vera and essential thrombocythemia: N- and K-ras mutations and microsatellite instability in chromosomes 5 and 7 in 69 patients.
    Mavrogianni D; Viniou N; Michali E; Terpos E; Meletis J; Vaiopoulos G; Madzourani M; Pangalis G; Yataganas X; Loukopoulos D
    Int J Hematol; 2002 May; 75(4):394-400. PubMed ID: 12041671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent.
    Higuchi T; Okada S; Mori H; Niikura H; Omine M; Terada H
    Cancer; 1995 Jan; 75(2):471-7. PubMed ID: 7812918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polycythemia vera.
    Murphy S
    Dis Mon; 1992 Mar; 38(3):153-212. PubMed ID: 1587207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute leukemia in polycythemia vera.
    Landaw SA
    Semin Hematol; 1976 Jan; 13(1):33-48. PubMed ID: 766188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.
    Berk PD; Goldberg JD; Donovan PB; Fruchtman SM; Berlin NI; Wasserman LR
    Semin Hematol; 1986 Apr; 23(2):132-43. PubMed ID: 3704665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
    Swolin B; Rödjer S; Westin J
    Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute leukemia following treatment of polycythemia vera and essential thrombocythemia with uracil mustard.
    Toh BT; Gregory SA; Knospe WH
    Am J Hematol; 1988 May; 28(1):58-60. PubMed ID: 3369437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
    Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
    Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute leukemia and myelodysplasia in polycythemia vera. A clinical study with long-term follow-up.
    Najean Y; Deschamps A; Dresch C; Daniel MT; Rain JD; Arrago JP
    Cancer; 1988 Jan; 61(1):89-95. PubMed ID: 3334954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.
    Alvarez-Larrán A; Pérez-Encinas M; Ferrer-Marín F; Hernández-Boluda JC; Ramírez MJ; Martínez-López J; Magro E; Cruz Y; Mata MI; Aragües P; Fox ML; Cuevas B; Montesdeoca S; Hernández-Rivas JA; García-Gutiérrez V; Gómez-Casares MT; Steegmann JL; Durán MA; Gómez M; Kerguelen A; Bárez A; García MC; Boqué C; Raya JM; Martínez C; Albors M; García F; Burgaleta C; Besses C;
    Haematologica; 2017 Jan; 102(1):103-109. PubMed ID: 27686377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor lysis syndrome induced by hydroxyurea therapy for leukemic transformation of polycythemia vera.
    Ellis AK; Lee DH
    Am J Hematol; 2002 Nov; 71(3):237-8. PubMed ID: 12410589
    [No Abstract]   [Full Text] [Related]  

  • 19. [Leukemic transformation of polycythemia vera after treatment with hydroxyurea and chromosome 17 abnormalities].
    Tóthová E; Nebesnáková E; Kafková A; Stecová N; Fricová M
    Vnitr Lek; 1999 Aug; 45(8):487-9. PubMed ID: 11045151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic complications of polycythemia vera.
    Varma S; Sharma A; Malhotra P; Kumari S; Jain S; Varma N
    Hematology; 2008 Dec; 13(6):319-23. PubMed ID: 19055858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.